布地奈德
医学
肾病
抗体
免疫学
内分泌学
哮喘
糖尿病
作者
David Wimbury,Masahiro Muto,Jasraj S. Bhachu,Katrin Scionti,Jeremy R. Glissen Brown,Karen Molyneux,Claudia Seikrit,Dita Maixnerová,Laura Pérez‐Alós,Peter Garred,Jürgen Floege,Vladimı́r Tesař,Bengt Fellström,Rosanna Coppo,Jonathan Barratt
标识
DOI：10.1016/j.kint.2023.11.003
摘要
Targeted-release budesonide modifies key pathogenic biomarkers inimmunoglobulin A nephropathy: Insights from the NEFIGAN trial Biomarkers with significant changes from baseline at 9 months with Nefecon 16 mg/d CONCLUSION Nefecon exerts a direct disease-modifying effect in IgAN by targeting the GALT, regulating mucosal immune dysfunction and potentially modulating the systemic immune response
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
浮游
吴彦祖
freyaaaaa
义气的水蓝
GingerF
tuanheqi
MchemG
xxfsx
yznfly
无极微光
超级宛白
娄心昊
GPTea
且慢
mashibeo
herococa
franklin_fsz
pual
搜集达人
qiuqiu
vivi
研友_8yPY0Z
从容芮
Hayat
皖公网安备34019202002308
